Biogen and Ionis Pharmaceuticals said Thursday that the European Commission has granted a marketing authorization for Spinraza in the treatment of 5q spinal muscular atrophy. Biogen was responsible for the commercialization of the drug and Ionis is eligible for milestone payments and royalties.
Ionis said it has earned a $50 million milestone payment from Biogen in connection with the EU approval. Ionis is also eligible to receive tiered sales royalties and has earned more than $375 million from Biogen to date. Spinraza is the first approved treatment in the EU for the condition, a genetic cause of death in infants. The drug was reviewed under the European Medicines Agency’s accelerated assessment program, intended to expedite access to patients with unmet medical needs.